Hogan Lovells advises Sentynl Therapeutics on FDA approval of ZYCUBO®

Press releases | 11 February 2026

Washington, D.C., Los Angeles – Global law firm Hogan Lovells advised Sentynl Therapeutics Inc. in connection with its recent U.S. Food and Drug Administration approval for ZYCUBO® (copper histidinate), the first and only treatment approved for Menkes disease, a rare and fatal genetic condition, in pediatric patients in the United States.

Menkes disease is a rare X-linked recessive pediatric disease caused by mutations of the copper transporter ATP7A encoded by the ATP7A gene. Patients with Menkes disease are born with the inability to absorb dietary copper and subsequently have impaired copper transport across the blood-brain barrier, and, until now, there has been no approved treatment in the United States. ZYCUBO® is a subcutaneous injectable formulation of copper histidinate that restores copper homeostasis and maintains copper levels in patients with Menkes disease.

The Hogan Lovells team that advised on this approval included partners Robert Church and Sally Gu, counsel Elizabeth McGuire, senior associates Eman Al-Hassan and Eva Marie Schifini, and senior director Christopher Middendorf.